1 / 1

Newsletter : Pompe Disease Newsletter

An autosomal metabolic disorder u2013 Pompe disease results in deterioration of organs and tissues as a consequence of excess accumulation of glycogen in muscle and nerve cells throughout the body. Also called Glycogen Storage disease type II, Pompe disease affects around 5,000 to 10,000 people worldwide, with an equal preponderance in Males and females.<br><br>DelveInsight's newsletter series brings to light an overview of Pompe disease, underlying cause, Etiology, Symptoms, Market and Epidemiology.<br><br>Top companies involved :<br>Tetra Therapeutics, Zynerba Pharmaceuticals, Ovid Therapeutics, Confluence Pharmaceuticals, and Neuren Pharmaceuticals.<br><br>Have a Copy our Newsletter : https://www.delveinsight.com/whitepaper-newsletter/pompe-disease

sthakur
Télécharger la présentation

Newsletter : Pompe Disease Newsletter

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pompe Disease Newsletter An autosomal metabolic disorder – Pompe disease results in deterioration of organs and tissues as a consequence of excess accumulation of glycogen in muscle and nerve cells throughout the body. Also called Glycogen Storage disease type II, Pompe disease affects around 5,000 to 10,000 people worldwide, with an equal preponderance in Males and females. DelveInsight's newsletter series brings to light an overview of Pompe disease, underlying cause, Etiology, Symptoms, Market and Epidemiology. Top companies involved : Tetra Therapeutics, Zynerba Pharmaceuticals, Ovid Therapeutics, Confluence Pharmaceuticals, and Neuren Pharmaceuticals. Have a Copy our Newsletter : https://www.delveinsight.com/whitepaper-newsletter/pompe- disease

More Related